In this context, RAS inhibitors and SGLT2 inhibitors are expected to contribute to balancing human health and the environment, due to their effectiveness in preventing the progression of CKD and the onset of cardiovascular disease. The gene discussed is SLC5A2; the disease is cardiovascular disorder.